Drug intelligence / Profile preview

ZDZ-553

Development stage: Preclinical
Lead developer: Southwest University

Overview

ZDZ-553: sourced facts only. name: "Using our established STAT1 inhibitor screening platform, we identified the compound ZDZ-553, which is characterized by a chromone skeleton, demonstrates potent inhibitory activity against STAT1, and exhibits a favorable safety profile." [PMID:41589317]; target: "Using our established STAT1 inhibitor screening platform, we identified the compound ZDZ-553, which is characterized by a chromone skeleton, demonstrates potent inhibitory activity against STAT1, and exhibits a favorable safety profile." [PMID:41589317]; developer: "College of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China." [PMID:41589317]; stage: "In the NASH mouse model experiment, ZDZ-553 significantly ameliorated liver steatosis and inflammatory responses." [PMID:41589317]

Targets

STAT1 (Signal transducer and activator of transcription protein 1)

Beyond the preview

Go deeper on ZDZ-553.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZDZ-553.